NL300537I2 - - Google Patents

Download PDF

Info

Publication number: NL300537I2
Authority: NL; Netherlands
Prior art keywords: sub; atoms; nitrogen; formula; fused
Prior art date: 2001-07-31

Application number

NL300537C

Other languages

English (en)

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2012-06-28

Publication date

2017-02-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300537(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-28 Application filed by Genzyme Corp filed Critical Genzyme Corp

2017-02-02 Publication of NL300537I2 publication Critical patent/NL300537I2/nl

Links

IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
125000003118 aryl group Chemical group 0.000 abstract 3
125000004122 cyclic group Chemical group 0.000 abstract 3
229910052757 nitrogen Inorganic materials 0.000 abstract 3
125000002947 alkylene group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
210000000130 stem cell Anatomy 0.000 abstract 2
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000000468 ketone group Chemical group 0.000 abstract 1
125000005647 linker group Chemical group 0.000 abstract 1
125000002950 monocyclic group Chemical group 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
229920000768 polyamine Polymers 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NL300537C 2001-07-31 2012-06-28 NL300537I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US30919601P	2001-07-31	2001-07-31
US38215502P	2002-05-20	2002-05-20
PCT/US2002/024212 WO2003011277A2 (en)	2001-07-31	2002-07-30	Methods to mobilize progenitor/stem cells

Publications (1)

Publication Number	Publication Date
NL300537I2 true NL300537I2 (nl)	2017-02-02

Family

ID=26976666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NL300537C NL300537I2 (nl)	2001-07-31	2012-06-28
NL301031C NL301031I2 (nl)	2001-07-31	2020-01-22	Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NL301031C NL301031I2 (nl)	2001-07-31	2020-01-22	Plerixafor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of metaalcomplex daarvan

Country Status (29)

Country	Link
US (9)	US6987102B2 (nl)
EP (3)	EP1411918B1 (nl)
JP (2)	JP5137288B2 (nl)
KR (2)	KR100996378B1 (nl)
CN (2)	CN102302493B (nl)
AT (1)	ATE538785T1 (nl)
AU (1)	AU2002318927B2 (nl)
BE (1)	BE2019C544I2 (nl)
BR (1)	BRPI0211570B8 (nl)
CA (1)	CA2455559C (nl)
CY (4)	CY1112633T1 (nl)
DK (2)	DK2371361T3 (nl)
ES (2)	ES2380009T3 (nl)
FR (2)	FR12C0042I1 (nl)
HK (1)	HK1063005A1 (nl)
HU (1)	HUP0402360A2 (nl)
IL (2)	IL159312A0 (nl)
LT (2)	LT2371361T (nl)
LU (2)	LU92033I2 (nl)
MX (1)	MXPA04000982A (nl)
NL (2)	NL300537I2 (nl)
NO (4)	NO336989B1 (nl)
NZ (1)	NZ530169A (nl)
PL (1)	PL364673A1 (nl)
PT (2)	PT2371361T (nl)
RU (1)	RU2309741C2 (nl)
SI (2)	SI2371361T1 (nl)
WO (1)	WO2003011277A2 (nl)
ZA (1)	ZA200400658B (nl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0211570B8 (pt) *	2001-07-31	2021-05-25	Anormed Inc	uso de 1'-[1,4-fenileno-bis-(metileno)-bis-1,4,8,11- tetrazaciclotetradecano ou um sal farmaceuticamente aceitável do mesmo na preparação de uma composição para coletar células progenitoras e/ou tronco
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
IL161784A0 (en)	2001-12-21	2005-11-20	Anormed Inc	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) *	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
JP4667241B2 (ja) *	2003-06-27	2011-04-06	旭化成株式会社	細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株
WO2005002522A2 (en) *	2003-06-30	2005-01-13	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Compositions and methods for treating tissue ischemia
US7417026B2 (en)	2003-08-13	2008-08-26	Children's Hospital Medical Center	Mobilization of hematopoietic cells
JP2007535479A (ja)	2003-08-13	2007-12-06	チルドレンズホスピタルメディカルセンター	ＧＴＰａｓｅを調節するためのキメラペプチド
IL158868A0 (en) *	2003-11-13	2004-05-12	Yeda Res & Dev	Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) *	2004-04-20	2005-11-03	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
BRPI0514343A (pt) *	2004-08-13	2008-06-10	Anormed Inc	combinações de quimiocinas para mobilizar células progenitoras/tronco
US7785582B2 (en) *	2004-09-07	2010-08-31	Johnson Lanny L	Use of synovium and omentum for tissue engineering
US8182806B2 (en) *	2004-09-07	2012-05-22	Johnson Lanny L	Synovial villi for use with tissue engineering
WO2006137934A2 (en)	2004-11-05	2006-12-28	The General Hospital Corporation	Purposeful movement of human migratory cells away from an agent source
CA2612102C (en)	2005-06-13	2016-02-09	Cleveland Biolabs, Inc.	Methods of protecting against apoptosis using lipopeptides
CA2619828A1 (en) *	2005-08-19	2007-02-22	Genzyme Corporation	Methods to enhance chemotherapy
EP1924606A4 (en) *	2005-08-25	2010-01-13	Repair Technologies Inc	DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
US8518349B2 (en)	2005-09-12	2013-08-27	Lanny Johnson	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US7927630B2 (en) *	2005-09-12	2011-04-19	Johnson Lanny L	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) *	2005-11-18	2007-05-24	Rensselaer Polytechnic Institute	Stem cells within gel microenvironments
CN101389329A (zh) *	2006-02-24	2009-03-18	健赞股份有限公司	增加血流和/或促进组织再生的方法
WO2007108689A2 (en) *	2006-03-21	2007-09-27	Stichting Skeletal Tissue Engineering	Method for induction of differentiation of stem and progenitor cells
AR062271A1 (es) *	2006-08-07	2008-10-29	Genzyme Corp	Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
US7883698B2 (en) *	2007-01-17	2011-02-08	Maria Michejda	Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (en) *	2008-08-29	2010-03-04	Genzyme Corporation	Cxcr4 antagonists for kidney injury
WO2011053700A1 (en) *	2009-10-28	2011-05-05	Henry Ford Health System	Methods to mitigate injury from radiation exposure
CN101716167B (zh) *	2009-12-08	2011-12-28	中国人民解放军军事医学科学院野战输血研究所	一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US20150030561A1 (en)	2011-05-16	2015-01-29	Genzyme Corp.	Use of CXCR4 Antagonists
EP2968563A4 (en) *	2013-03-15	2016-11-30	Leonard B Miller	COMBINED TREATMENT TO IMPROVE MOU TISSUE HEALING, HEALING ADIPOSE TISSUE GRAFT, ENDOCHREST BONE SEWAGE AND OSTEOINTEGRATION
US9988973B2 (en)	2015-01-06	2018-06-05	Hamilton Sundstrand Corporation	Water injector for aviation cooling system
AU2016324160A1 (en)	2015-09-18	2018-04-26	The General Hospital Corporation Dba Massachusetts General Hospital	Localized delivery of anti-fugetactic agent for treatment of cancer
US10953003B2 (en)	2015-12-14	2021-03-23	X4 Pharmaceuticals, Inc.	Methods for treating cancer
WO2017106332A1 (en)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methods for treating cancer
WO2017106630A1 (en)	2015-12-18	2017-06-22	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
ES2935834T3 (es)	2015-12-22	2023-03-10	X4 Pharmaceuticals Inc	Métodos para tratar enfermedad de inmunodeficiencia
WO2017177230A1 (en)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Methods for treating cancer
WO2017216373A1 (en) *	2016-06-16	2017-12-21	Centre National De La Recherche Scientifique	Cxcr4 receptor-binding compounds useful for increasing interferon level
CA3027498A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
CN109640988A (zh)	2016-06-21	2019-04-16	X4 制药有限公司	Cxcr4抑制剂及其用途
EP3472129A4 (en)	2016-06-21	2019-12-04	X4 Pharmaceuticals, Inc.	CXCR4 INHIBITORS AND USES THEREOF
US11453706B2 (en)	2016-09-09	2022-09-27	The General Hospital Corporation	HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
EP3509609A4 (en)	2016-09-09	2021-01-20	The General Hospital Corporation	HYBRID HSP PROTEIN WITH ANTI-CHEMIO-REPELLENT AGENT FOR CANCER TREATMENT
WO2018049120A1 (en)	2016-09-09	2018-03-15	The General Hospital Corporation	Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
WO2018106738A1 (en)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Brush-arm star polymers, conjugates and particles, and uses thereof
US10058573B1 (en)	2017-12-06	2018-08-28	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem cells
BR112020011186A2 (pt) *	2017-12-06	2020-11-17	Magenta Therapeutics, Inc.	regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP3900712A1 (en) *	2017-12-19	2021-10-27	GPCR Therapeutics, Inc.	Gpcr heteromer inhibitors and uses thereof
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
US20230193212A1 (en)	2020-05-06	2023-06-22	Orchard Therapeutics (Europe) Limited	Treatment for neurodegenerative diseases
WO2023056444A1 (en)	2021-10-01	2023-04-06	Janssen Pharmaceutica N.V.	Methods of increasing progenitor cell production

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US562476A (en) *		1896-06-23		Combined fence-wire reel and straightener
US4111199A (en) *	1977-03-31	1978-09-05	Isaac Djerassi	Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de)	1987-08-24	1989-03-16	Schering Ag	Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) *	1989-03-20	1990-09-21	Centre Nat Rech Scient	Procede de preparation de tetramines cycliques monofonctionnalisees
DE69032374T2 (de)	1989-10-23	1998-12-17	Nycomed Salutar Inc	Mehrzähnige metall-chelatierende verbindungen
US5021409A (en) *	1989-12-21	1991-06-04	Johnson Matthey Plc	Antiviral cyclic polyamines
US6001826A (en)	1989-12-21	1999-12-14	Anormed, Inc.	Chemical compounds
FR2672051B1 (fr) *	1991-01-24	1993-05-21	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en)	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en) *	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
WO1994011027A1 (en)	1992-11-13	1994-05-26	Board Of Regents Of University Of Washington	Peripheralization of hematopoietic stem cells
GB9400411D0 (en)	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5612478A (en)	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) *	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) *	1995-06-05	1997-02-25	Nippon Kayaku Co Ltd	末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en)	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
GB9511357D0 (en)	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US5811544A (en) *	1995-08-28	1998-09-22	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (en)	2000-05-09	2001-11-09	The University Of British Columbia	Cxcr4 antagonist treatment of hematopoietic cells
EP1068357B2 (en) *	1998-03-30	2014-12-10	NorthWest Biotherapeutics, Inc.	Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
AU4696899A (en)	1998-06-19	2000-01-05	General Hospital Corporation, The	Modulating platelet function
CA2244554A1 (en) *	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition of graft versus host disease
IL142094A0 (en)	1998-09-29	2002-03-10	Gamida Cell Ltd	Methods of controlling proliferation and differentiation of stem and progenitor cells
EP1133291B1 (en)	1998-11-17	2006-01-11	Smithkline Beecham Corporation	Cyclic polyamines for treating thrombocytopenia
EP1016413A1 (en) *	1998-12-30	2000-07-05	Applied Research Systems ARS Holding N.V.	Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) *	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
BR0010655A (pt)	1999-03-24	2002-02-13	Anormed Inc	Compostos heterocìclicos para ligação ao receptor de quimiocina
AU4692400A (en) *	1999-05-03	2000-11-17	Smithkline Beecham Corporation	Cxcr-4 receptor antagonists - thrombopoietin mimetics
CA2389545C (en)	1999-12-17	2010-08-31	Anormed Inc.	Chemokine receptor binding heterocyclic compounds
ATE265219T1 (de)	2000-05-09	2004-05-15	Univ British Columbia	Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
AU2001275339A1 (en) *	2000-06-05	2001-12-17	The Trustees Of Columbia University In The City Of New York	Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
ES2269465T3 (es)	2000-09-15	2007-04-01	Anormed Inc	Compuestos heterociclicos de union a los receptores de la quimioquina.
ATE420873T1 (de)	2000-09-15	2009-01-15	Anormed Inc	Chemokin rezeptor bindenden heterozyklische verbindungen
US6864265B2 (en)	2000-09-15	2005-03-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
WO2002026721A1 (en)	2000-09-29	2002-04-04	Anormed Inc.	Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
JP2004517908A (ja)	2001-01-23	2004-06-17	ピーアンドジー−クレイロール・インコーポレイテッド	毛髪の酸化的着色のための一次中間体
BRPI0211570B8 (pt)	2001-07-31	2021-05-25	Anormed Inc	uso de 1'-[1,4-fenileno-bis-(metileno)-bis-1,4,8,11- tetrazaciclotetradecano ou um sal farmaceuticamente aceitável do mesmo na preparação de uma composição para coletar células progenitoras e/ou tronco
US7169750B2 (en)	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
IL161784A0 (en)	2001-12-21	2005-11-20	Anormed Inc	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de)	2014-03-31	2018-01-18	BSH Hausgeräte GmbH	Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

2002
- 2002-07-30 BR BRPI0211570 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 EP EP02750370A patent/EP1411918B1/en not_active Revoked
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
- 2002-07-30 CA CA2455559A patent/CA2455559C/en not_active Expired - Lifetime
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko active IP Right Grant
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/en not_active Expired - Lifetime
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/en active Search and Examination
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Application Discontinuation
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/en not_active Withdrawn
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
- 2004-06-18 HK HK04104446.8A patent/HK1063005A1/xx not_active IP Right Cessation
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en active Active
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I1/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I2/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown

Also Published As

Publication number	Publication date
EP1411918A2 (en)	2004-04-28
US7897590B2 (en)	2011-03-01
US7935692B2 (en)	2011-05-03
US20060193826A1 (en)	2006-08-31
CN102302493B (zh)	2015-08-12
EP2371361A1 (en)	2011-10-05
LUC00139I2 (nl)	2021-02-10
US20190216773A1 (en)	2019-07-18
US20060223180A1 (en)	2006-10-05
US20170049747A1 (en)	2017-02-23
IL159312A0 (en)	2004-06-01
NO2020003I1 (no)	2020-03-05
KR100996378B1 (ko)	2010-11-25
CY2019038I1 (el)	2020-05-29
PT1411918E (pt)	2012-03-06
HK1063005A1 (en)	2004-12-10
CY1112633T1 (el)	2015-08-05
FR19C1058I1 (nl)	2019-11-22
WO2003011277A2 (en)	2003-02-13
NO20150674A1 (no)	2015-05-27
DK1411918T3 (da)	2012-04-23
US20110129448A1 (en)	2011-06-02
ATE538785T1 (de)	2012-01-15
KR20040020075A (ko)	2004-03-06
NO344632B1 (no)	2020-02-17
NL301031I1 (nl)	2020-02-05
BE2019C544I2 (nl)	2021-07-19
NO2016011I1 (no)	2016-06-10
AU2002318927B2 (en)	2007-01-04
CA2455559C (en)	2012-01-10
SI1411918T1 (sl)	2012-04-30
LU92033I2 (fr)	2012-08-27
JP2004538303A (ja)	2004-12-24
CY1122199T1 (el)	2020-05-29
JP2008195730A (ja)	2008-08-28
FR19C1058I2 (fr)	2020-10-23
LU92033I9 (nl)	2019-01-03
WO2003011277A3 (en)	2003-05-22
CN102302493A (zh)	2012-01-04
HUP0402360A2 (hu)	2005-02-28
LTC2371361I2 (lt)	2021-09-27
NO20040407L (no)	2004-03-19
US20150246019A1 (en)	2015-09-03
IL159312A (en)	2015-05-31
JP5137288B2 (ja)	2013-02-06
PT2371361T (pt)	2019-09-10
DK2371361T3 (da)	2019-08-19
EP1411918B1 (en)	2011-12-28
PL364673A1 (en)	2004-12-13
BR0211570A (pt)	2004-07-13
LTPA2019018I1 (lt)	2019-12-10
US6987102B2 (en)	2006-01-17
EP2371361B1 (en)	2019-08-07
FR12C0042I1 (fr)	2012-08-10
CN1561208B (zh)	2010-11-10
MXPA04000982A (es)	2004-04-20
NL301031I2 (nl)	2020-07-20
LUC00139I1 (nl)	2019-11-27
EP1411918A4 (en)	2007-11-14
CY2012017I2 (el)	2015-08-05
ES2380009T3 (es)	2012-05-07
CN1561208A (zh)	2005-01-05
US20080063624A1 (en)	2008-03-13
KR20090130152A (ko)	2009-12-17
US20030130250A1 (en)	2003-07-10
NZ530169A (en)	2007-04-27
RU2309741C2 (ru)	2007-11-10
ES2742730T3 (es)	2020-02-17
CA2455559A1 (en)	2003-02-13
CY2012017I1 (el)	2015-08-05
US20130273009A1 (en)	2013-10-17
SI2371361T1 (sl)	2019-10-30
RU2004105961A (ru)	2005-03-20
LT2371361T (lt)	2019-09-10
BRPI0211570B1 (pt)	2020-01-28
ZA200400658B (en)	2005-07-27
NO336989B1 (no)	2015-12-14
CY2019038I2 (el)	2020-05-29
EP3632425A1 (en)	2020-04-08
BRPI0211570B8 (pt)	2021-05-25

Publication	Publication Date	Title
LUC00139I2 (nl)	2021-02-10
AP1497A (en)	2005-11-20	Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu)	2001-04-28	VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR930006027A (ko)	1993-04-20	엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
KR920012082A (ko)	1992-07-25	Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
ES2164164T3 (es)	2002-02-16	Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
EA200501148A1 (ru)	2006-04-28	Пиридилоксиметильные и бензизоксазольные азабициклические производные
DE3573119D1 (en)	1989-10-26	8-alkylthio-2-piperazino-pyrimidoû5,4-d¨pyrimidines, their preparation and medicaments containing them
WO1999023092A3 (en)	1999-08-05	3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
EP1142883A4 (en)	2002-08-21	HETEROCYCLIC COMPOUNDS AND MEDICINAL COMPOSITIONS THAT CONTAIN THEM
OA09239A (fr)	1992-06-30	"Nouveaux céphèmes et procédés pour leur préparation".
MY133207A (en)	2007-10-31	Substituted benzolactam compaunds
WO2007106063A3 (en)	2007-12-21	Methods for increasing blood flow and/or promoting tissue regeneration
EP1057829A4 (en)	1999-12-10	Condensed pyrimidine derivatives and pharmaceutical compositions containing them
ES8605524A1 (es)	1986-03-16	Procedimiento para preparar tieno- y furo-(2,3-c)-pirroles